28.12.2012 Views

THE FUTURE, - Solvay

THE FUTURE, - Solvay

THE FUTURE, - Solvay

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

209749 209799<br />

MEDEXIS: MANAGING AND INTERLINKING<br />

INFORMATION USED BY OCCUPATIONAL<br />

PHYSICIANS AND HYGIENISTS ON<br />

WORKPLACE RISKS<br />

Medexis: a worldwide<br />

observatory for better health<br />

at work<br />

<strong>THE</strong> PROJECT. Medexis is a database which<br />

exploits individual medical data by associating<br />

them with information on the exposure of <strong>Solvay</strong><br />

personnel to chemicals and other hazardous<br />

products. Medexis has been developed on SAP<br />

and is fully integrated with other SAP modules,<br />

which is a fi rst. This is a worldwide project,<br />

designed to ensure a fl ow of complete,<br />

standardized and reliable data in areas that were<br />

previously separate: scientifi c, toxicological and<br />

regulatory information on substances, noise and<br />

vibration, exposure levels of each employee, and<br />

individual medical follow-up.<br />

The system will make it possible to establish new<br />

correlations between working conditions and<br />

health, to identify as yet unknown health issues<br />

and to take decisions more effectively to improve<br />

the situation.<br />

The system is also a management tool designed<br />

to manage all hygiene and occupational medicine<br />

activities in the <strong>Solvay</strong> group at both local and<br />

corporate level (follow-up of actions and results,<br />

scorecard and indicators, internal benchmarking,<br />

costs of services, etc.). Medexis will also make it<br />

possible to share best practices and best<br />

prevention strategies worldwide. The deployment<br />

of this system is one of the Group’s 25 key<br />

sustainable development objectives - the goal<br />

being to implement it at 80% of Group sites by<br />

2012.<br />

CC HSE<br />

> Christiane Baleux; Willy Asnong;<br />

Nathalie Berne; Jean-Paul Capelle; Pierre Coërs;<br />

Stéphanie Gauzente; Philippe Hannequart;<br />

Aline Huge; Thomas Paschek; Brigitte Sion;<br />

Jack Smit; Paul Vanhemelryck.<br />

CDM PROJECT THROUGH RECOVERY OF<br />

SF6 FROM GAS-INSULATED EQUIPMENT IN<br />

TESTING FACILITIES<br />

SF6 contributes to<br />

the Kyoto objectives<br />

<strong>THE</strong> PROJECT. The CDM (Clean Development<br />

Mechanism) project benefi ts from the fl exibility of<br />

the Kyoto Protocol which states that developing<br />

countries such as Korea may contribute to the<br />

reduction of greenhouse gas emissions by<br />

participating in international ‘emission trading’<br />

under United Nations supervision.<br />

Specifi cally, the SF6 (sulfur hexafl uoride) gas<br />

which serves as insulation in electrical systems<br />

tested at KERI (Korea Electrotechnology Research<br />

Institute) is recovered, transported, processed and<br />

recycled by <strong>Solvay</strong> Fluor instead of being<br />

discharged to the atmosphere.<br />

This partnership project is at the development<br />

stage. The methodology was approved in March<br />

2009 and it should be validated in August 2009,<br />

verifi ed in 2010, and implemented for the fi rst<br />

time in 2011.<br />

It will provide additional income to <strong>Solvay</strong>, along<br />

with energy and raw materials savings (up to<br />

10 tons of SF6 per year) and contribute to the<br />

Group’s reputation in Korea, with an image as a<br />

leader in environmental protection and<br />

sustainable development.<br />

SBU FLUOR<br />

> Seung-Bong Choi; Dae-Jun Han; Ho-Jin Jeon;<br />

Hans-Jürgen Korte.<br />

209824<br />

<strong>THE</strong> SOLVAY ANIMAL CARE AND USE<br />

COMMITTEE: AN INDEPENDENT OVERSIGHT<br />

GROUP OF EXPERTS FROM OUTSIDE AND<br />

INSIDE <strong>THE</strong> COMPANY<br />

A better life for animals<br />

<strong>THE</strong> PROJECT. To be sustainable, all <strong>Solvay</strong><br />

activities must be justifi able and acceptable to<br />

society as well as to the people that work for the<br />

Group. The Executive Committee has adopted an<br />

animal policy which includes the creation of an<br />

independent oversight committee, the <strong>Solvay</strong><br />

group Animal Care and Use Committee or SACUC.<br />

Independence is important when ethical and<br />

moral considerations might potentially confl ict<br />

with business goals. With an equal numbers of<br />

external and internal experts with specialist<br />

knowledge of animal experimentation, animal<br />

alternatives and animal ethics, the committee<br />

gives advice to <strong>Solvay</strong>’s most senior managers on<br />

the care, use and protection of animals and on<br />

replacement, reduction and refi nement (the 3 Rs)<br />

in the use of all animals.<br />

PHARMACEUTICALS SECTOR<br />

> Roger Bickerstaffe; Pierre Coërs;<br />

Jacques de Gerlache; Bruno Schmit;<br />

Susanne Thun-Battersby.<br />

<strong>Solvay</strong> <strong>Solvay</strong> live live - JUILLET - JULY 2009 - 51

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!